Compare Organon & Co. Common Stock (OGN) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard High Dividend Yield ETF trades at $159.6 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 27.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| OGN | VYM | |
|---|---|---|
Market Cap | $3.61B | $100.80B |
Volume | 1,808,049 | 1,062,392 |
Sector | Health | — |
52-Week High | $13.81 | $167.03 |
52-Week Low | $5.70 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VYM trades at $159.11, down slightly by 0.08% on the day. The ETF shows a bullish technical signal overall, with moving averages supporting an uptrend, though oscillators are neutral. Recent news highlights its consistent dividend yield of 2.42% but questions its performance versus peers like SCHD and IDV. Key support sits at $158, with resistance at $160.
The outlook for VYM hinges on its dividend reliability amid competition from higher-yielding or better-performing ETFs. Risks include exposure to dividend cuts in holdings like Intel and Walgreens. Analyst sentiment is mixed, favoring a hold rating due to moderate returns compared to alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
